Until now, the most successful application of CAR-T therapy has been CD19-targeted CARs toward B cell malignancies such as non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and ALL (15). Here, CD19 is linked to acute lymphoblastic leukemia.